Related Experiment Video

Updated: Aug 20, 2026

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel Film
04:09

Development and Characterization of Fusidic Acid-Loaded Alginate-Aloe vera Based Hydrogel Film

Published on: December 13, 2024

Development of a long-acting insulin analog using albumin fusion technology

Alokesh Duttaroy1, Palanisamy Kanakaraj, Blaire L Osborn

  • 1Division of Diabetes, Endocrinology and Metabolic Diseases, NIDDK/NIH, 6707 Democracy Blvd., Rm. 606, MSC5460, Bethesda, MD 20892-5460, USA.

Diabetes
|December 24, 2004
PubMed

Insights

Albulin, a novel long-acting insulin analog, offers sustained 24-hour basal glycemia in diabetic mice. This gene-fusion therapy shows potential for improved diabetes management when combined with fast-acting insulins.

Area of Science:

  • Biotechnology
  • Endocrinology
  • Pharmacology

Background:

  • Maintaining near-normal blood glucose levels is crucial for diabetes treatment and preventing complications.
  • Current long-acting insulin analogs offer limited duration of action, necessitating frequent dosing.
  • A need exists for insulin therapies providing stable, long-lasting basal glycemic control.

Purpose of the Study:

  • To develop and characterize Albulin, a novel long-acting insulin analog with extended duration of action.
  • To evaluate the in vitro and in vivo pharmacodynamic properties of Albulin.
  • To assess the potential of Albulin as a new therapeutic option for insulin-dependent diabetes.

Main Methods:

  • Albulin was created by direct gene fusion of single-chain human insulin to human serum albumin.
  • In vitro assays assessed Albulin's receptor binding, gluconeogenesis inhibition, and glucose uptake.
  • In vivo studies in diabetic mice evaluated Albulin's pharmacokinetic and pharmacodynamic profiles, including blood glucose normalization.

Main Results:

  • Albulin demonstrated an elimination half-life of approximately 7 hours in normoglycemic mice.
  • In vitro studies showed Albulin possesses similar activity profiles to recombinant human insulin.
  • A single Albulin administration normalized blood glucose levels in diabetic mice for a sustained 24-hour period.
  • Combination therapy with fast-acting insulin further enhanced glucose reduction.

Conclusions:

  • Albulin exhibits characteristics of a potent, long-acting insulin analog.
  • Albulin provides sustained basal glycemic control, potentially improving diabetes management.
  • This novel analog warrants further evaluation for clinical use in patients with insulin-dependent diabetes.

More Related Videos

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres09:31

Sustained Administration of β-cell Mitogens to Intact Mouse Islets Ex Vivo Using Biodegradable Poly(lactic-co-glycolic acid) Microspheres

Published on: November 5, 2016

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye06:10

Encapsulated Cell Technology for the Delivery of Biologics to the Mouse Eye

Published on: March 30, 2020

Related Concept Videos

Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Insulin: Biosynthesis, Chemistry, and Preparation01:25

Insulin: Biosynthesis, Chemistry, and Preparation

The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment primarily uses...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...